Cannabis Sativa, Inc. (CBDS) Stock Analysis

Cannabis Sativa, Inc. (CBDS) Healthcare & Pipeline Overview

Cannabis Sativa, Inc. operates PrestoDoctor, an online telemedicine platform for medical marijuana recommendations, alongside developing and marketing a diverse portfolio of hemp-derived cannabinoid products. The company also holds intellectual property for medical marijuana edibles, positioning it within the evolving healthcare and wellness sectors, focusing on cannabis-related services and goods.

What Is the Investment Thesis for CBDS?

Cannabis Sativa, Inc. presents an investment profile centered on its dual approach to the cannabis market: a telemedicine platform and a diversified product line. The PrestoDoctor platform addresses a critical need for accessible medical marijuana recommendations, leveraging the growing acceptance of virtual healthcare. The company's expansion into hemp-derived cannabinoid products like 'Recover' balm and 'Garden' skincare lines taps into the expanding wellness market, offering multiple revenue streams. With a gross margin of 64.6%, the company demonstrates efficiency in its cost of goods sold, indicating potential for improved profitability as scale is achieved. However, the current profit margin of -89.3% highlights significant operational challenges and the need for substantial revenue growth and cost control to reach profitability. The high Beta of 2.86 indicates considerable price volatility relative to the broader market, reflecting the inherent risks of operating in the highly regulated and evolving cannabis sector. Future growth catalysts include potential federal or state-level regulatory changes that could expand market access, successful new product launches, and increased adoption of its telemedicine services. The company's intellectual property licenses for medical marijuana edibles also represent a long-term value driver, contingent on market entry and execution. Investors should monitor the company's ability to navigate regulatory hurdles, manage competition, and achieve sustainable profitability in this dynamic industry.

Based on FMP financials and quantitative analysis

CBDS Key Highlights

Cannabis Sativa, Inc. operates with a reported market capitalization of $4.27M, reflecting its micro-cap status within the market.

• The company maintains a gross margin of 64.6%, indicating a strong ability to cover its cost of goods sold from product and service revenues.
• A profit margin of -89.3% signifies that the company is currently operating at a substantial loss, requiring significant improvements in revenue and cost management.
• The stock exhibits a high Beta of 2.86, suggesting it is considerably more volatile than the overall market, which can lead to larger price swings.
• Cannabis Sativa, Inc. does not currently pay a dividend, consistent with its growth-oriented stage and negative profitability.

Who Are CBDS's Competitors?

CBDS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CBDS's Key Strengths?

Established online telemedicine platform (PrestoDoctor) for medical marijuana recommendations, addressing a growing market need.

• Diversified product portfolio including various hemp-derived balms, creams, and skincare, catering to multiple wellness segments.
• Ownership of intellectual property licenses for medical marijuana edibles, providing future growth potential.
• High gross margin of 64.6% indicates efficient cost management for products and services sold.

What Are CBDS's Weaknesses?

Negative profit margin of -89.3% indicates significant operational losses and challenges in achieving profitability.

• Small employee count of 4 suggests limited operational capacity and potential for scalability challenges.
• Listing on the OTC Other tier implies lower transparency, liquidity, and investor confidence compared to major exchanges.
• High Beta of 2.86 indicates significant stock price volatility, which can be a risk for investors.

What Could Drive CBDS Stock Higher?

CBDS catalyst: Potential for new product launches within the 'Wild Earth Naturals' or 'Garden' lines, expanding the company's market reach in the cannabinoid wellness sector.

• Expansion of PrestoDoctor telemedicine services into additional U.S. states where medical cannabis legalization is enacted or expanded, increasing user base and service revenue.
• Continued growth in consumer adoption of telemedicine for medical cannabis recommendations, driven by convenience and evolving healthcare preferences.
• Increasing mainstream acceptance and market demand for hemp-derived CBD products, providing a tailwind for the company's diversified product sales.
• Strategic partnerships or licensing agreements to monetize its intellectual property for medical marijuana edibles manufacturing, unlocking a new revenue stream.

What Are the Key Risks for CBDS?

Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.

• Significant negative profit margin of -89.3% indicates persistent operational losses, posing a challenge to long-term financial viability without substantial revenue growth and cost control.
• Highly competitive landscape in both the telemedicine for cannabis and the broader CBD/hemp product markets, potentially limiting market share and pricing power.
• Adverse changes in state or federal regulations pertaining to cannabis and CBD products, which could impact the legality, marketing, or distribution of the company's offerings.
• Risks associated with the OTC Other listing, including limited liquidity, lack of transparency, and difficulty in attracting institutional investment, which can hinder capital raising efforts.
• Dependence on the success and adoption of its relatively small portfolio of products and services, with any single product failure having a disproportionate impact on overall performance.

What Are the Growth Opportunities for CBDS?

• **Expansion of Telemedicine Services:** The PrestoDoctor platform offers a significant growth avenue by capitalizing on the ongoing shift towards virtual healthcare and the increasing demand for accessible medical marijuana recommendations. As of 2026, the telemedicine market continues its robust expansion, driven by convenience and technological advancements. Cannabis Sativa, Inc. can expand its reach by securing licenses in additional states where medical cannabis is legal, thereby increasing its user base and service revenue. Further enhancements to the platform, such as integrating more comprehensive patient support or expanding physician networks, could solidify its market position and capture a larger share of the virtual medical consultation market, which is projected to grow substantially over the next five years.
• **Diversification into New Cannabinoid Product Lines:** Cannabis Sativa, Inc.'s strategy of developing and marketing a diverse range of hemp-derived cannabinoid products, including 'Recover' healing balm, 'Trauma Cream,' and the 'Garden' skincare line, presents a strong growth opportunity. The global CBD market is projected to reach significant valuations, driven by increasing consumer awareness of its potential therapeutic benefits. By continuously innovating and introducing new formulations that target specific wellness needs, the company can expand its market share within the competitive health and beauty sectors. Focusing on product efficacy, unique ingredient profiles, and effective marketing can differentiate these offerings and attract a broader consumer base, particularly within the growing natural and alternative wellness product segments.
• **Leveraging Intellectual Property for Edibles Manufacturing:** The company's ownership of intellectual property licenses pertinent to the manufacturing of medical marijuana edibles represents a substantial, yet currently untapped, growth opportunity. The edibles market within the cannabis industry is one of the fastest-growing segments, appealing to consumers seeking alternative consumption methods to smoking. By strategically partnering with licensed manufacturers or developing its own production capabilities in compliant jurisdictions, Cannabis Sativa, Inc. could introduce branded medical marijuana edibles. This move would allow the company to enter a high-demand product category, diversify its revenue streams beyond services and topical products, and capitalize on its existing IP, potentially unlocking significant value in the mid-to-long term.
• **Growth in the Broader CBD/Hemp Wellness Market:** The increasing mainstream acceptance and consumer interest in cannabidiol (CBD) and other hemp-derived wellness products provide a broad market tailwind for Cannabis Sativa, Inc. As scientific research continues to emerge and regulatory clarity improves, more consumers are exploring CBD for various health and wellness purposes, including pain relief, anxiety reduction, and skincare. The company's 'Wild Earth Naturals' and 'hi' brands, along with its specialized balms and creams, are well-positioned to capture a share of this expanding market. Strategic marketing, e-commerce optimization, and potential expansion into retail partnerships could significantly boost sales and brand recognition within the burgeoning wellness sector over the next 3-5 years.
• **Potential for Favorable Regulatory Changes:** The evolving regulatory landscape surrounding cannabis in the United States offers a significant growth opportunity. As of 2026, more states are considering or implementing medical and recreational cannabis legalization, and there is ongoing discussion at the federal level regarding decriminalization or rescheduling of cannabis. Any positive federal regulatory changes could significantly reduce operational complexities, open up new markets, facilitate interstate commerce, and potentially attract institutional investment. Such changes could lower banking restrictions, improve access to capital, and reduce the stigma associated with cannabis businesses, thereby creating a more favorable operating environment for Cannabis Sativa, Inc. and accelerating its growth trajectory.

What Threats Does CBDS Face?

• Intense competition from established and emerging players in both the telemedicine and cannabinoid product markets.
• Ongoing regulatory uncertainty and potential changes in cannabis laws at state and federal levels, which could impact operations.
• Challenges in achieving profitability and managing operating expenses in a highly competitive and capital-intensive industry.
• Risks associated with OTC Other listing, including limited liquidity, potential for price manipulation, and difficulty in raising capital.

What Are CBDS's Competitive Advantages?

• Established online telemedicine platform (PrestoDoctor) providing a convenient and accessible pathway for medical marijuana recommendations.
• Diversified product portfolio spanning various wellness categories, from topical balms to skincare, reducing reliance on a single product line.
• Ownership of intellectual property licenses for medical marijuana edibles, offering potential for future market entry and product differentiation.
• Early mover advantage in specific niches of the evolving cannabis and CBD wellness markets, building brand recognition.

What Does CBDS Do?

Cannabis Sativa, Inc., established in November 2013 and formerly known as Ultra Sun Corporation, is headquartered in Mesquite, Nevada, and operates primarily through its various subsidiaries in the United States. The company's core business revolves around offering online telemedicine referral services, specifically facilitating access to medical marijuana cards. Its flagship platform, PrestoDoctor, is a prominent online telemedicine service that enables individuals to connect virtually with licensed physicians via video conferencing. This virtual consultation model allows users to efficiently secure medical cannabis recommendations, addressing a significant demand within the regulated medical marijuana landscape. Beyond its foundational telemedicine offerings, Cannabis Sativa, Inc. has strategically diversified its product portfolio. This includes the development and marketing of a range of hemp-based and cannabinoid-infused products designed for various wellness applications. Notable products include specialized lozenges formulated for throat irritation relief, 'Recover,' a deep-penetrating healing balm targeting discomfort in sore muscles, joints, arthritis, and back pain, and 'Trauma Cream,' a topical blend infused with cannabinoids and THC. The company has also ventured into the skincare market with its 'Garden' line, featuring 'Face Garden' (an antioxidant moisturizing cream), 'Body Garden' (a moisturizing lotion), and 'Lip Garden' (an emollient balm). Further extending its brand presence, Cannabis Sativa, Inc. markets branded merchandise, such as men's and women's fashion t-shirts, sweatshirts, caps, and coffee mugs, under its 'Wild Earth Naturals' and 'hi' labels, available through its wildearthnaturals.com website. Additionally, the company holds valuable intellectual property licenses pertinent to the manufacturing of medical marijuana edibles, positioning it for potential expansion into this segment. Active within both the cannabidiol (CBD) and broader marijuana industries, Cannabis Sativa, Inc. aims to capitalize on the growing consumer interest in alternative wellness products containing cannabinoids while navigating a complex regulatory environment.

What Products and Services Does CBDS Offer?

• Operates PrestoDoctor, an online telemedicine platform connecting individuals with physicians for medical marijuana recommendations.
• Develops and markets 'Recover,' a deep-penetrating healing balm for muscle, joint, arthritis, and back pain relief.
• Produces 'Trauma Cream,' a topical blend infused with cannabinoids and THC for localized discomfort.
• Offers a 'Garden' line of skincare products, including 'Face Garden' (antioxidant moisturizing cream), 'Body Garden' (moisturizing lotion), and 'Lip Garden' (emollient balm).
• Markets lozenges formulated for throat irritation relief.
• Sells branded merchandise, such as t-shirts, sweatshirts, caps, and coffee mugs, under 'Wild Earth Naturals' and 'hi' labels.
• Holds intellectual property licenses related to the manufacturing of medical marijuana edibles.
• Engages in both the cannabidiol (CBD) and broader marijuana industries through its diverse product and service offerings.

How Does CBDS Make Money?

• Generates revenue through fees for online telemedicine consultations via its PrestoDoctor platform, facilitating medical marijuana card recommendations.
• Earns income from the direct sale of its proprietary hemp-derived and cannabinoid-infused wellness products, including balms, creams, and skincare lines.
• Monetizes its intellectual property by holding licenses pertinent to the manufacturing of medical marijuana edibles, potentially through future partnerships or direct production.
• Sells branded merchandise under its 'Wild Earth Naturals' and 'hi' labels through its e-commerce website, contributing to brand visibility and revenue.

What Industry Does CBDS Operate In?

Cannabis Sativa, Inc. operates within the rapidly evolving and highly dynamic cannabis and cannabidiol (CBD) industries, specifically positioning itself in the medical cannabis telemedicine and hemp-derived wellness product segments. The broader cannabis market continues to experience significant growth, driven by increasing legalization efforts across various U.S. states for both medical and recreational use, alongside growing consumer acceptance of cannabis and CBD for health and wellness. The telemedicine sector, particularly for medical cannabis recommendations, has seen accelerated adoption, fueled by convenience and regulatory shifts allowing virtual consultations. Cannabis Sativa, Inc.'s PrestoDoctor platform directly addresses this trend, competing with other online health providers and traditional clinics. In the hemp-derived product space, the company faces a fragmented and competitive landscape with numerous brands offering CBD balms, creams, and skincare. While the overall market for CBD products is projected to expand, differentiation through product efficacy, brand recognition, and intellectual property will be crucial. The industry is heavily influenced by state and federal regulations, which can create both opportunities and significant operational challenges for companies like Cannabis Sativa, Inc.

Who Are CBDS's Key Customers?

• Individuals in the United States seeking medical marijuana cards through a convenient, virtual consultation process.
• Consumers interested in alternative wellness solutions for discomfort, pain relief, and general well-being using hemp-derived cannabinoid products.
• Customers seeking natural and antioxidant-rich skincare products for facial and body care.
• Enthusiasts of cannabis-related brands looking for branded apparel and accessories.

Company Profile

Cannabis Sativa, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in Mesquite, US. The company is led by CEO David M. Tobias. CBDS has traded publicly since 2012.

Return on equity for Cannabis Sativa, Inc. stands at 36.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -30.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -4.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.04 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -48.9%, the inverse of the P/E and a quick read on earnings relative to price.

CBDS Valuation & Market Position

With a $4.27M market cap, Cannabis Sativa, Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: Cannabis Sativa, Inc.

Revenue for Cannabis Sativa, Inc. came in at $193K during Q1 2026, a 12.5% improvement versus the preceding quarter. The company recorded a net loss of $198K, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CBDS averaged $-0.04 in diluted EPS.

Cannabis Sativa, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.

Over the past six months, Cannabis Sativa, Inc. insiders filed 8 SEC Form 4 transactions — 8 sales and 0 purchases. On net that is roughly 1.6M shares disposed (about $17K), a signal worth weighing alongside the fundamentals.

CBDS Financials

CBDS Latest News

No recent news available for CBDS.

Common Questions About CBDS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources